Abstract：
BACKGROUND: The use of subtalar arthroereisis as an adjunct to the surgical treatment of stage 1 flexible progressive collapsing foot deformity (PCFD) is controversial. The aim was to investigate the clinical outcomes and report the implant removal rate of subtalar arthroereisis as an adjunct for stage 1 PCFD.
METHODS: A retrospective study of 212 consecutive feet undergoing operative management of stage 1 PCFD with adjunctive subtalar arthroereisis between October 2010 and April 2018. The primary outcome was the Foot and Ankle Outcome Score (FAOS). Secondary outcomes included Foot and Ankle Disability Index (FADI), Euroqol-5D-5L Index and implant removal rate.
RESULTS: Post-operative clinical FAOS outcomes were collected for 153 feet (72.2%). At mean 2.5-year follow-up, the mean ± standard deviation FAOS for each domain was as follows; Pain: 81.5 ± 18.5, Symptoms: 79.5 ± 12.9, Activities of Daily Living: 82.5 ± 15.4 and Quality of Life: 64.2 ± 23.7. EQ-5D-5L Index was 0.884 ± 0.152. Pre-operative scores were available for 20 of these feet demonstrating a statistically significant improvement in all FAOS, FADI and EQ-5D-5L domains (p < 0.05). The implant removal rate for persistent sinus tarsi pain was 48.1% (n = 102).
CONCLUSIONS: Use of a subtalar arthroereisis implant as an adjunct to conventional procedures in stage 1 flexible PCFD can result in significant improvement in pain and function. Patients should be counselled as to the relatively frequent rate of subsequent implant removal.
METHODS: IV.
METHODS: A retrospective study of 212 consecutive feet undergoing operative management of stage 1 PCFD with adjunctive subtalar arthroereisis between October 2010 and April 2018. The primary outcome was the Foot and Ankle Outcome Score (FAOS). Secondary outcomes included Foot and Ankle Disability Index (FADI), Euroqol-5D-5L Index and implant removal rate.
RESULTS: Post-operative clinical FAOS outcomes were collected for 153 feet (72.2%). At mean 2.5-year follow-up, the mean ± standard deviation FAOS for each domain was as follows; Pain: 81.5 ± 18.5, Symptoms: 79.5 ± 12.9, Activities of Daily Living: 82.5 ± 15.4 and Quality of Life: 64.2 ± 23.7. EQ-5D-5L Index was 0.884 ± 0.152. Pre-operative scores were available for 20 of these feet demonstrating a statistically significant improvement in all FAOS, FADI and EQ-5D-5L domains (p < 0.05). The implant removal rate for persistent sinus tarsi pain was 48.1% (n = 102).
CONCLUSIONS: Use of a subtalar arthroereisis implant as an adjunct to conventional procedures in stage 1 flexible PCFD can result in significant improvement in pain and function. Patients should be counselled as to the relatively frequent rate of subsequent implant removal.
METHODS: IV.
摘要：
背景：使用距下关节作为一期柔性进行性塌陷性足畸形（PCFD）手术治疗的辅助手段是有争议的。目的是研究临床结果，并报告距下关节作为1期PCFD辅助治疗的植入物去除率。
方法：一项回顾性研究，在2010年10月至2018年4月期间，对212只连续足进行了1期PCFD手术治疗并辅助距下关节。主要结果是足踝结局评分（FAOS）。次要结局包括足踝残疾指数(FADI)，Euroqol-5D-5L指数和植入物去除率。
结果：收集153英尺（72.2%）的术后临床FAOS结果。在平均2.5年的随访中，每个领域的平均±标准差FAOS如下;疼痛:81.5±18.5,症状:79.5±12.9,日常生活活动:82.5±15.4,生活质量:64.2±23.7。EQ-5D-5L指数为0.884±0.152。这些脚中有20个的术前评分，表明所有FAOS都有统计学上的显着改善，FADI和EQ-5D-5L结构域(p<0.05)。持续的关节窦痛的植入物去除率为48.1％（n=102）。
结论：在1期柔性PCFD中，使用距下关节植入物作为常规手术的辅助治疗可以显著改善疼痛和功能。应向患者咨询后续植入物移除的相对频繁的速率。
方法：IV.
方法：一项回顾性研究，在2010年10月至2018年4月期间，对212只连续足进行了1期PCFD手术治疗并辅助距下关节。主要结果是足踝结局评分（FAOS）。次要结局包括足踝残疾指数(FADI)，Euroqol-5D-5L指数和植入物去除率。
结果：收集153英尺（72.2%）的术后临床FAOS结果。在平均2.5年的随访中，每个领域的平均±标准差FAOS如下;疼痛:81.5±18.5,症状:79.5±12.9,日常生活活动:82.5±15.4,生活质量:64.2±23.7。EQ-5D-5L指数为0.884±0.152。这些脚中有20个的术前评分，表明所有FAOS都有统计学上的显着改善，FADI和EQ-5D-5L结构域(p<0.05)。持续的关节窦痛的植入物去除率为48.1％（n=102）。
结论：在1期柔性PCFD中，使用距下关节植入物作为常规手术的辅助治疗可以显著改善疼痛和功能。应向患者咨询后续植入物移除的相对频繁的速率。
方法：IV.
